BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Blumberg EA, Manuel O, Sester M, Ison MG. The future of SARS-CoV-2 vaccines in transplant recipients: To be determined. Am J Transplant 2021;21:2629-30. [PMID: 33829628 DOI: 10.1111/ajt.16598] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Schmidt T, Klemis V, Schub D, Schneitler S, Reichert MC, Wilkens H, Sester U, Sester M, Mihm J. Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. Am J Transplant 2021. [PMID: 34453872 DOI: 10.1111/ajt.16818] [Cited by in Crossref: 52] [Cited by in F6Publishing: 26] [Article Influence: 52.0] [Reference Citation Analysis]
2 Yamada M, Matsumoto E, Thomas CP, Carlson JR, Klutts JS, Kumar B, Streit JA, Swee ML. Case Report: Severe COVID-19 in a Kidney Transplant Recipient Without Humoral Response to SARS-CoV-2 mRNA Vaccine Series. Transplant Direct 2021;7:e743. [PMID: 34386580 DOI: 10.1097/TXD.0000000000001193] [Reference Citation Analysis]
3 Miele M, Busà R, Russelli G, Sorrentino MC, Di Bella M, Timoneri F, Mularoni A, Panarello G, Vitulo P, Conaldi PG, Bulati M. Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients. Am J Transplant 2021;21:2919-21. [PMID: 34058052 DOI: 10.1111/ajt.16702] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 31.0] [Reference Citation Analysis]